Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

Antibiotic resistance is a major health problem and will be probably one of the leading
causes of deaths in the coming years. One of the most effective ways to fight against …

The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae
(ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems …

Antibiotics have been the most important risk factor for Clostridium difficile infection (CDI).
However, only data from non-randomised studies have been reviewed. We sought to …

The antibiotic pipeline continues to diminish and the majority of the public remains unaware
of this critical situation. The cause of the decline of antibiotic development is multifactorial …

Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high
mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a …

Introduction: β-lactams have been consistently associated with the majority of drug-related
adverse events. Generally, these are mild under proper dosing and judicious selection …

Background Ceftazidime/avibactam is approved for complicated intra-abdominal and urinary
tract infections (UTIs) based on results from randomized controlled trials (RCTs). Data …

Introduction: The spread of extended-spectrum β–lactamase (ESBL)-producing
Enterobacteriaceae has become a major public health threat worldwide. Area covered: A …

ABSTRACT β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in
two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase …